Interestingly, low-dose IL-2 expanded nTregs expressing high levels of CD25, retained their suppressive capacity and reduced disease activity in SLE patients (Von Spee-Mayer et al. 2016; He et al. 2016). The gene discussed is IL2; the disease is systemic lupus erythematosus.